ArticleJournal of cancer research and clinical oncology2025
MRI-based radiomics signatures for predicting the efficacy of targeted therapy with lenvatinib in hepatocellular carcinoma: a retrospective cohort study.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTargeted therapy with lenvatinib is a preferred option for advanced hepatocellular carcinoma, however, predicting its efficacy remains challenging. This study aimed to build a nomogram integrating clinicoradiological indicators and radiomics features to predict the response to lenvatinib in patients with hepatocellular carcinoma.
methodsThis study included 211 patients with hepatocellular carcinoma from two centers, who were allocated into the training (107 patients), internal test (46 patients) and external test set(58 patients). Radiomics features were extracted using a Pyradiomics-based system. Biopsy specimens were used for immunohistochemical staining of epidermal growth factor receptor. Risk factors for predicting treatment response were screened out to construct models by logistic regression analysis. The performance of models was evaluated with receiver operating characteristic and decision curve analyses.
resultsA total of 9370 radiomics features were extracted from five sequences. Subsequently, seven radiomics features were identified for modeling. Intratumoral vessel and expression level of epidermal growth factor receptor were independent risk factors for predicting treatment response to lenvatinib and were used to build a clinical model. No difference was found in predicting performance between clinical model and radiomics model. The combined model, integrating intratumoral vessel, epidermal growth factor receptor and radiomics features, had better predicting performance with areas under the receiver operating characteristic curve of 0.908, 0.877, and 0.870 for the training, internal test and external test sets, respectively.
conclusionThis study underscored the significant potential of radiomics features combined with clinicoradiological indicators in the prediction of treatment response to lenvatinib in patients with hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.